Literature DB >> 26202343

An Overview of Products and Bias in Research.

David Gloss1.   

Abstract

Cannabis is a genus of annual flowering plant. Cannabis is often divided into 3 species-Cannabis sativa, Cannabis indica, and Cannabis ruderalis-but there is significant disagreement about this, and some consider them subspecies of the same parent species. Cannabis sativa can grow to 5-18 feet or more, and often has a few branches. Cannabis indica typically grows 2-4 feet tall and is compactly branched. Cannabis ruderalis contains very low levels of Δ-9-tetrahyocannabinol so is rarely grown by itself. Cannabis ruderalis flowers as a result of age, not light conditions, which is called autoflowering. It is principally used in hybrids, to enable the hybrid to have the autoflowering property. There are > 700 strains of cannabis, often with colorful names. Some are strains of 1 of the 3 subspecies. Many are crossbred hybrids. The strains can be named in a variety of ways: smell or lineage are common ways of naming. There are only a few rules about how the strains are named, and most strains' names do not follow the rules. There are 4 basic preparations of marijuana: bhang, hasish, oil (or hash oil), and leaves and/or buds. In medical marijuana trials, subjective outcomes are frequently used but blind breaking can introduce significant bias. Blind breaking occurs when patients figure out if they are in the control or the treatment group. When this occurs, there is significant overestimation of treatment effect.

Entities:  

Keywords:  Bias; C. sativa; Cannabis; Medical marijuana

Mesh:

Substances:

Year:  2015        PMID: 26202343      PMCID: PMC4604179          DOI: 10.1007/s13311-015-0370-x

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  14 in total

1.  Medical marijuana's public health lessons--implications for retail marijuana in Colorado.

Authors:  Tista S Ghosh; Michael Van Dyke; Ali Maffey; Elizabeth Whitley; Dana Erpelding; Larry Wolk
Journal:  N Engl J Med       Date:  2015-03-12       Impact factor: 91.245

2.  An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.

Authors:  Jeremy R Johnson; Dominique Lossignol; Mary Burnell-Nugent; Marie T Fallon
Journal:  J Pain Symptom Manage       Date:  2012-11-08       Impact factor: 3.612

Review 3.  Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis.

Authors:  Fidelia Cascini; Carola Aiello; Gianluca Di Tanna
Journal:  Curr Drug Abuse Rev       Date:  2012-03

4.  Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops.

Authors:  F T A Pijlman; S M Rigter; J Hoek; H M J Goldschmidt; R J M Niesink
Journal:  Addict Biol       Date:  2005-06       Impact factor: 4.280

5.  Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial.

Authors:  Turo J Nurmikko; Mick G Serpell; Barbara Hoggart; Peter J Toomey; Bart J Morlion; Derek Haines
Journal:  Pain       Date:  2007-11-07       Impact factor: 6.961

6.  A new method of cannabis ingestion: the dangers of dabs?

Authors:  Mallory Loflin; Mitch Earleywine
Journal:  Addict Behav       Date:  2014-05-28       Impact factor: 3.913

7.  Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.

Authors:  Tibor M Brunt; Marianne van Genugten; Kathrin Höner-Snoeken; Marco J van de Velde; Raymond J M Niesink
Journal:  J Clin Psychopharmacol       Date:  2014-06       Impact factor: 3.153

Review 8.  Cannabinoids for epilepsy.

Authors:  David Gloss; Barbara Vickrey
Journal:  Cochrane Database Syst Rev       Date:  2014-03-05

9.  Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.

Authors:  Stephen Wright; Paul Duncombe; Douglas G Altman
Journal:  Trials       Date:  2012-10-09       Impact factor: 2.279

10.  Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile.

Authors:  Wendy Swift; Alex Wong; Kong M Li; Jonathon C Arnold; Iain S McGregor
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more
  8 in total

1.  Quantification of Cannabis in Infused Consumer Products and Their Residues on Skin.

Authors:  Rosalynn Quiñones; Sara Moreno; Amanda L Smythers; Carrie Sullins; Haley Pijor; Glenna Brown; Ashley Trouten; Lauren L Richards-Waugh; Aladin Siddig
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-18

2.  Nonmedical Marijuana Use and Cardiovascular Events: A Systematic Review.

Authors:  Peter K Yang; Erika C Odom; Roshni Patel; Fleetwood Loustalot; Sallyann Coleman King
Journal:  Public Health Rep       Date:  2021-02-26       Impact factor: 2.792

Review 3.  A Comprehensive Review on the Techniques for Extraction of Bioactive Compounds from Medicinal Cannabis.

Authors:  Hebah Muhsien Sabiah Al Ubeed; Deep Jyoti Bhuyan; Muhammad A Alsherbiny; Amrita Basu; Quan V Vuong
Journal:  Molecules       Date:  2022-01-18       Impact factor: 4.411

Review 4.  Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.

Authors:  Krzysztof Laudanski; Justin Wain
Journal:  J Clin Med       Date:  2022-01-22       Impact factor: 4.241

Review 5.  Cannabis Associated Mental Health Effects: A Review.

Authors:  Neeraj Kancherla; Keerthana Mani Jeyanthi; Ramsha Abbas; Thanmay Sai Charaan Reddy Sathi; Amrita Upadhyay; Sameer Krishna Prasad Garlapati
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

6.  Identification and mapping of major-effect flowering time loci Autoflower1 and Early1 in Cannabis sativa L.

Authors:  Jacob A Toth; George M Stack; Craig H Carlson; Lawrence B Smart
Journal:  Front Plant Sci       Date:  2022-09-21       Impact factor: 6.627

7.  A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products.

Authors:  Qingfang Meng; Beth Buchanan; Jonathan Zuccolo; Mathieu-Marc Poulin; Joseph Gabriele; David Charles Baranowski
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

Review 8.  Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?

Authors:  Luisa Rocha; Christian Lizette Frías-Soria; José G Ortiz; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2020-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.